Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Karina Rossi Bonfiglioli1*, Licia Maria Henrique da Mota2, Ana Cristina de Medeiros Ribeiro1, Adriana Maria Kakehashi3, Ieda Maria Magalhães Laurindo4, Rina Dalva Neubarth Giorgi5, Angela Luzia Branco Duarte6, Ana Paula Monteiro Gomides Reis3, Mariana Peixoto Guimarães Ubirajara e Silva de Souza7, Claiton Viegas Brenol8, Geraldo da Rocha Castelar Pinheiro9, Cleandro Pires de Albuquerque2, Charles Heldan de Moura Castro10, Gustavo Luiz Behrens Pinto11, Jose Fernando Verztman12, Luciana Feitosa Muniz13, Manoel Barros Bertolo14, Maria Raquel da Costa Pinto9, Paulo Louzada Júnior15, Vitor Alves Cruz16, Ivanio Alves Pereira17, Max Vitor Carioca de Freitas18, Boris Afonso Cruz19, Eduardo Paiva20, Odirlei Monticielo8, Jose Roberto Provenza21 and Ricardo Machado Xavier8

Abstract

Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.

Introduction

Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease characterized by involvement of the synovial membrane of peripheral joints. If not treated early and adequately, the disease can cause bone erosion and irreversible joint deform(554,578),(819,600) increased morbidity and mortality and a significant impact on the quality of life of the affected individual [1]. RA affects up to 1% of the general population and is more common in women aged 40 to 60 years [2].

In the last 3 decades, there has been significant evolution in the management of patients with RA, with emphases on early diagnosis, rigorous monitoring of disease activity and goal-oriented treatment strategies. A better understanding of its pathophysiology has led to the development of new disease-modifying antirheumatic drugs (DMARDs), primarily biological DMARDs...
(bDMARDs) and, more recently, targeted synthetic DMARDs (tsDMARDs). The treatment objectives remain reducing joint and systemic inflammation with the aims of inhibiting disease progression, preventing loss of functionality and preserving patient quality of life [3–5].

Despite the various therapeutic options available, there are patients who do not achieve the desired response (remission or low disease activity) due to an inadequate clinical response (primary failure) or loss of response (secondary failure) or drug toxicity [6].

According to the most recent recommendations of the Brazilian Society of Rheumatology (SBR, for its initials in Portuguese) [1] and the European Alliance of Associations for Rheumatology (EULAR) [7], the main objective of RA treatment is to achieve sustained clinical remission or, in cases where this is not possible, low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs [1, 7].

New RA therapeutic targets are emerging. Janus kinases (JAKs), enzymes involved in intracellular signaling (JAK-STAT pathway), are essential to the control of response of many cytokines involved in the immunopathogenesis of RA. Therefore, JAK inhibitors (JAKis) have shown efficacy in the treatment of RA [8]. JAKis currently approved for commercialization in Brazil include tofacitinib [9] (JAK1 and JAK3 inhibitor), baricitinib [10] (JAK1 and JAK2 inhibitor) and upadacitinib [11] (selective JAK1 inhibitor).

**Objective**

The objective of these recommendations is to present a review, directed to rheumatologists, of the main aspects related to the efficacy and safety of JAKis in RA patients and to update the recommendations and treatment algorithm proposed by the SBR in 2017 [1].

**Method**

This review followed a protocol developed by the members of the SBR Rheumatoid Arthritis Committee, who established questions based on real-life scenarios, that can be accessed in Additional files.

For the purposes of these recommendations, the following acronym and nomenclature system was adopted:

- **DMARDs**
  - Disease-modifying antirheumatic drugs;

- **csDMARDs**
  - Conventional synthetic disease-modifying antirheumatic drugs—methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ) and hydroxychloroquine (HCQ);

- **bDMARDs**
  - Biological disease-modifying antirheumatic drugs—tumor necrosis factor (TNFα-i) inhibitors adalimumab (ADA), certolizumab (CTZ), etanercept (ETA), golimumab (GOLI) and infliximab (IFX) and drugs with other mechanisms of non-TNFα-i action, i.e., abatacept (ABA), rituximab (RTX) and tocilizumab (TCZ);

- **tsDMARDs**
  - Targeted synthetic disease-modifying antirheumatic drugs (JAK inhibitors)—baricitinib (BARI), tofacitinib (TOFA), upadacitinib (UPA), filgotinib (FILGO) and peficitinib (PEFI);

- **JAKi**
  - Janus Kinase inhibitor

- **mTSS**
  - Modified total Sharp score;

- **HAQ-DI**
  - Health Assessment Questionnaire Disability Index;

- **NSAIDs**
  - Nonsteroidal antiinflammatory drugs;

- **DAS28-CRP**
  - Disease activity score 28/C-reactive protein.

- **DAS28-ESR**
  - Disease activity score 28/erythrocyte sedimentation rate.

- **CDAI**
  - Clinical Disease Activity Index.

- **SDAI**
  - Simplified Disease Activity Index.

- **Remission**
  - DAS28-CRP and/or DAS28-ESR < 2.6; and.

- **Low disease activity**
  - DAS28-CRP and/or DAS28-ESR ≥ 2.6 < 3.2.

- **RCT**
  - Randomized controlled trial.

To answer the selected questions, systematic literature reviews (SLRs) were performed for each specific scenario.

**Elements of study eligibility**

The search for evidence was performed in virtual scientific information databases using search strategies specific to each question.

The searches in these databases were performed until the month corresponding to the completion and submission of these guidelines for publication, and a systematic review was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [12].

The following data were extracted from the studies: name of the author and year of publication, population...
studied, methods of intervention and comparison, absolute number of events, and follow-up time.

The risk of bias in randomized clinical trials was analyzed based on the following criteria: randomization, blinded allocation, double blinding, losses, prognostic characteristics, presence of expected outcome, time to outcome, outcome measurement method, sample calculation, early interruption, and presence of other biases.

The measures used to express benefits and harms varied based on the outcomes and were expressed as continuous variables (mean and standard deviation) or categorical variables (absolute number of events). For continuous measures, the results reflect differences in means and standard deviation, and for categorical measures, the results reflect differences in risks and number needed to treat or produce harm, considering the number of patients. The confidence level was set at 95%. The results underwent meta-analysis when common outcomes among studies were observed.

The results of the included studies were aggregated and meta-analyzed using RevMan 5.4 software [13].

In addition, the quality of the evidence was scored as high, moderate, low or very low using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) instrument [14], taking into account the risk of bias, the presence of inconsistencies, imprecise or indirect evidence in the meta-analysis of outcomes and the presence of publication bias.

The search strategies, selection process, characteristics and evaluation of the methodological quality of the included studies, as well as the synthesis of the results and quality of the evidence (based on GRADE), are available online as appendices.

Elaboration of recommendations
The process of drafting the recommendations relied on the participation of the SBR Rheumatoid Arthritis Committee, that included 27 rheumatologists from a panel of experts. Based on the SLR results for each clinical question as well as on the clinical experience of the experts, recommendations were elaborated and subjected to online voting.

The first step involved agreeing about the structure and content of each of the propositions, requiring 70% agreement for inclusion of the proposition. When this value was not attained, the propositions were reformulated and submitted to a new voting stage until 70% agreement was met. Subsequently, the level of agreement was established based on the content in the propositions: the panel of experts assigned a degree of agreement using a numerical scale from 0 ("strongly disagree") to 10 ("strongly agree") for each recommendation.

Results
A summary of the search and synthesis of the evidence for each SLR performed is presented below, based on the proposed clinical questions. In all scenarios, adult patients (> 18 years old) who met the RA classification criteria of the American College of Rheumatology (ACR) of 1987 [15] or the 2010 ACR/EULAR criteria [16] were evaluated. All the details on the selection of studies, reasons for exclusion, list of excluded studies, and analysis of the quality of the evidence for the outcomes are available in the corresponding appendices of this publication.

Efficacy and safety of tsDMARDs (JAKis) under different scenarios

1. Are tsDMARDs (JAKis) safe and effective as a first-line treatment for RA patients? (ps.: treatment-naïve patients)

A total of 403 studies were retrieved, individually accessed by title and/or abstract but only 3 were selected to support this evaluation. The reasons for exclusion and the list of excluded studies are available in the Additional file 1: Appendix 1 of this publication [17–19].

Evidence summary
The following evidence pertains to adult patients with recent onset RA (symptoms < 6 months) or established RA (symptoms ≥ 6 months), regardless of disease activity, who received a nontherapeutic dose or no csDMARDs/bDMARDs.

Results within 6 months
- TOFA (5 mg 12/12 h), BARI (4 mg/day) and UPA (15 or 30 mg/day), all in monotherapy, compared to MTX, led to a higher proportion of patients who achieved ACR (20%-50%-70%) and DAS28-ESR (remission and low activity) responses. There was also more significant improvement in functional capacity (measured by the HAQ-DI) in patients who received TOFA, BARI and UPA monotherapy. The quality of the evidence supporting these results is high.
- BARI (4 mg/day) monotherapy compared to BARI+MTX did not show superiority in any response criterion.

Results within 13 months
- BARI (4 mg/day) compared to MTX, both monotherapies, led to a higher proportion of patients who achieved an ACR response (20%-50%-70%) but not DAS28-ESR (remission or low activity). There was also more significant improvement in functional
capacity, as measured by HAQ-DI. The quality of the evidence supporting this result is high.

- BARI (4 mg/day) monotherapy compared to BARI + MTX combined therapy showed no superiority in any response criterion.
- BARI (4 mg/day) + MTX combined therapy compared to MTX monotherapy led to a higher proportion of patients who achieved DAS28-ESR (remission and low activity). The quality of the evidence supporting this result is high.

Safety

- TOFA (5 mg 12/12 h) monotherapy and BARI (4 mg/day) monotherapy or in combination with MTX demonstrated acceptable safety compared to MTX monotherapy in the initial treatment of patients with active RA, based on assessments of severe adverse events (SAEs). The quality of the evidence supporting this result is high.
- MTX and UPA (15 mg/day) showed similar occurrences of SAEs. However, UPA at a dose of 30 mg/day had a higher risk of SAEs. The quality of the evidence supporting this result is moderate.

2. Are tsDMARDs (JAKis) safe and effective for the treatment of RA patients after csDMARD failure?

The search for evidence resulted in a total of 1658 articles. After reading the titles and abstracts, 1581 studies were excluded. The full texts of 77 studies were accessed, of which 19 [20–38] were selected to support this evaluation. (Additional file 2: Appendix 2).

Evidence summary

The following evidence pertains to patients with moderate or high RA activity after DMARD failure, followed by treatment with a JAKi.

In monotherapy or in combination with MTX/other csDMARDs, or,

Compared with placebo in combination with MTX/other csDMARDs.

- TOFA (5 mg 12/12 h or 10 mg 12/12 h), alone or combined with MTX, improves ACR response outcomes (20%-50%-70%) and DAS28-ESR (remission and low activity). There was also improvement in functional capacity (measured by the HAQ-DI). The quality of evidence supporting this result is high.
- BARI (2 mg/day and 4 mg/day) monotherapy or combined with MTX led to a higher proportion of patients who achieved an ACR response (20%-50%-70%) and low disease activity and remission, as determined by DAS28-CRP and DAS28-ESR, in addition to significant improvement in functional capacity (as measured by the HAQ-DI). The quality of the evidence supporting this result is high/moderate.
- UPA (15 mg/day) monotherapy or combined with MTX led to a higher proportion of patients who achieved an ACR response (20–50–70) and low disease activity and remission, as determined by DAS28-CRP and DAS28-ESR. The quality of the evidence supporting this result is high/moderate.
- FILGO (100 mg/day and 200 mg/day) monotherapy led to a higher proportion of patients who achieved ACR 50, ACR 70, and low disease activity and remission, as determined by DAS28-CRP and DAS28-ESR, with moderate quality of evidence. However, the quality of evidence for improvements in ACR 20 and the HAQ-DI score are moderate and low, respectively. PEFI (100 mg/day and 150 mg/day) as a monotherapy or combined with MTX led to a higher proportion of patients who achieved an ACR response (20–50–70), remission, as determined by DAS28-CRP and DAS28-ESR, and low disease activity, as determined by DAS28-CRP. The quality of the evidence supporting this result is low/very low.

Safety

All JAKis, alone or in combination with MTX, showed acceptable safety compared to placebo for patients with moderate or high RA after failure of regimens with different csDMARDs, as determined by analyzing SAEs. The quality of evidence for this outcome ranged from moderate to very low. To better understand/define the safety of JAKis, more phase 4 studies are needed.

3. Are tsDMARDs (JAKis) safe and effective for the treatment of RA patients after bDMARD failure?

In the search for evidence, 58 studies were retrieved and individually assessed by title and/or abstract; 4 [39–42] references were selected for evaluation of their full texts. (Additional file 3: Appendix 3).

Evidence summary

The following evidence pertains to patients with a diagnosis of established RA who had an inadequate response to treatment with bDMARDs, followed by treatment with tsDMARDs (JAKis), either as a monotherapy or in combination with methotrexate or other csDMARDs, in comparison with placebo.

Results within 3 months
TOFA, BARI, and FILGO led to a higher proportion of patients who achieved an ACR response (20%–50%–70%) in 3 months.

UPA led to a higher proportion of patients who achieved ACR 20 and 50 responses in 3 months.

TOFA led to a higher proportion of patients who reached low activity (DAS28-ESR) in 3 months.

BARI led to a higher proportion of patients who achieved low activity and remission (DAS28-ESR) in 3 months.

FILGO and UPA led to a higher proportion of patients who reached low activity (DAS28-CRP) in 3 months.

There was improvement in functional capacity (measured by HAQ-DI) for all JAKis, in 3 months.

The quality of the evidence supporting these results is high.

Safety
All JAKis, alone or in combination with MTX, after failure of bDMARDs, showed acceptable safety compared to placebo, as determined by analyzing SAEs. The quality of evidence supporting these results is high.

Effectiveness, safety and cost of tsDMARDs (JAKis) in relation to csDMARDs and bDMARDs

4. Are tsDMARDs (JAKis) more effective than csDMARDs in the treatment of RA?

In the search for evidence, 1325 studies were retrieved and individually assessed by title and/or abstract, from which 42 references were selected for evaluation of their full texts. Of the 42 studies, 4 [17, 19, 43, 44] randomized clinical trials were selected to support this evaluation, i.e., JAKis (TOFA, BARI and UPA) compared with MTX. A flow diagram is provided in the online supplementary Additional file 4: Appendix 4.

Evidence summary
The following evidence pertains to adult patients who met the RA classification criteria of the ACR or ACR/EULAR 2010 and in whom the the use of JAKis (TOFA, BARI and UPA) and csDMARDs (MTX) was compared.

Results within 3–6 months

- UPA (15 mg/day and 30 mg/day) monotherapy, compared to MTX, led to a higher proportion of patients who achieved ACR 20% and 50% responses in 3 months. A higher proportion of patients also achieved clinical remission (DAS28-PCR) in 6 months. The quality of the evidence supporting this result is high.

- Compared with MTX, UPA (15 mg/day and 30 mg/day) after 6 months resulted in lower radiographic progression (Van der Heijde score) of RA. The quality of the evidence supporting this result is high.

Results within 6–12 months

- TOFA (5 mg 12/12 h and 10 mg 12/12 h), compared to MTX, both monotherapies, led to a higher proportion of patients who achieved an ACR (20–50%) response and low activity (DAS28-ESR). In 12 months, an ACR 70% response rate and remission, as determined by DAS28-ESR, were more frequent in patients who received TOFA. The quality of the evidence supporting this result is high.

- Compared with MTX, TOFA (5 mg 12/12 h and 10 mg 12/12 h) resulted in lower radiographic progression (modified Van der Heijde score) at 6 months. The quality of the evidence supporting this result is high.

- Compared with MTX, BARI (4 mg/day) monotherapy (or combined with MTX) led to a higher proportion of patients who achieved an ACR response (20%–50%–70%) and clinical remission (DAS28-ESR) at 6 and 12 months. The quality of the evidence supporting this result is high.

- Compared with MTX, BARI (4 mg/day) did not alter the risk of radiographic progression (Van der Heijde score). The quality of the evidence supporting this result is high.

Safety

- Compared with MTX monotherapy, TOFA (5 mg) monotherapy and BARI (4 mg) monotherapy or in combination with MTX demonstrated acceptable safety in the initial treatment of patients with active RA, as determined by analyzing SAEs. The quality of the evidence supporting this result is high.

- The adverse events resulting from treatment with MTX and UPA (15 mg/day) were similar, but there was a higher incidence of adverse events with 30 mg/day UPA. The quality of the evidence supporting this result is moderate.

5. Compared with bDMARDs, do tsDMARDs (JAKis) show evidence of greater efficacy for the treatment of RA?

In the search for evidence, 1442 studies were retrieved and individually assessed by title and/or abstract, from which 33 references were selected for evaluation of their
Evidence summary

The following evidence pertains to adult patients (>16 years) with recent onset RA (symptoms <6 months) and established RA (symptoms ≥6 months), regardless of disease activity, in whom the use of JAKis as a monotherapy or in combination with MTX was compared with the use of bDMARDs alone or combined with MTX.

Results within 6 months

- Compared to ADA + MTX, TOFA (5 mg 12/12 h) as a monotherapy did not lead to different ACR 20%, ACR 50%, and ACR 70% outcomes and was inferior to ADA + MTX regarding low activity outcomes (DAS28-ESR).
- TOFA (10 mg 12/12 h) was superior to ADA + MTX combined therapy with respect to ACR 70% outcomes; there was no difference between the treatments for the other outcomes. The quality of the evidence supporting this result is moderate.
- UPA (15 mg/day) combined with MTX, compared to ADA + MTX, led to a higher proportion of patients who achieved ACR 20% and 50% responses. The quality of the evidence supporting this result is moderate.
- Compared with ADA + MTX, UPA (15 mg/day) combined with MTX did not reduce the risk of radiographic progression (mTSS). The quality of the evidence supporting this result is moderate.

Results within 12 months

- Compared with ADA + MTX, TOFA (5 mg 12/12 h) as a monotherapy did not alter ACR 20%, 50%, and 70% outcomes and resulted in lower low activity and remission outcomes (DAS28-VHS) at 12 months.
- BARI (4 mg/day) combined with MTX, compared to ADA + MTX, led to a higher proportion of patients who achieved ACR 20% and 50% responses, with no difference for ACR 70% outcomes, remission and low activity (DAS28-PCR). The quality of the evidence supporting this result is moderate.
- Compared with ADA + MTX, BARI (4 mg/day) combined with MTX reduced the risk of radiographic progression (mTSS) at 6 and 12 months. The quality of the evidence supporting this result is moderate.

Safety

- The rate of SAEs at 6 and 12 months was higher in patients who used BARI than in those who used ADA. There was no difference in SAEs when comparing those for TOFA or UPA with ADA at the 6-month follow-up. The quality of the evidence supporting this result is moderate.

6. Is there evidence of better cost-effectiveness for DMARDs (JAKis) compared with csDMARDs?

In the search for evidence, 203 studies were retrieved and individually assessed by title and/or abstract, from which 16 references were selected for full text evaluation. Of the 16 studies, only 2 were selected to support this evaluation [49, 50]. A flow diagram is provided in the online supplementary Additional file 6: Appendix 6.

Evidence summary

In patients with moderate to severe active RA, tsDMARDs (JAKis), compared with csDMARDs, were cost-effective in patients with inadequate responses to biological therapy.

The literature, however, lacks studies that evaluate whether tsDMARDs are cost-effective when compared with csDMARDs after failure with another csDMARD. Future studies are needed to evaluate this scenario.

7. Is there evidence of better cost-effectiveness for tsDMARDs (JAKis) compared with bDMARDs?

Studies were evaluated for risk of bias using the Critical Appraisal Skills Program—CASP (economic) evaluation checklist [1]. In the search for evidence, 203 studies were retrieved and individually assessed by title and/or abstract, of which 16 references were selected for full text evaluation. Of the 16 studies, only 6 were selected to support this evaluation [51–57]. Supporting material is available online in the supplementary Additional file 7: Appendix 7.

Evidence summary

- Compared with the use of biological therapies (ADA, ETA, CERTOLI, RITUXI, ABATA and TOCILI), the use of JAKis (BARI and TOFA combined or not with MTX) is cost-effective in patients with active, moderate to severe RA, with inadequate response to csDMARDs or anti-TNF bDMARDs.
• Future studies are needed to evaluate the cost-effectiveness of JAKis compared to that of DMARDs in the Brazilian scenario, as well as the cost-effectiveness of other JAKis.

8. Is there evidence for vaccination effectiveness against herpes zoster (HZ) before starting treatment with JAKis?

Evidence indicates that the use of JAKis is accompanied by a higher risk of infection by HZ [58, 59].

In the search for evidence, 1909 studies were retrieved and individually assessed by title and/or abstract, from which 19 references were selected for full text evaluation. Finally, in regard to the eligibility criteria, 4 studies were included [60–63]; the reasons for exclusion are found in the online supplementary Additional file 8: Appendix 8.

Evidence summary

• The efficacy of the live attenuated HZ vaccine (LZV) is questionable in patients using JAKis, especially in combination with MTX. The quality of the evidence supporting this result is moderate.
• Therapy with TOFA has no negative impact on the established immune response after vaccination with LZV. The quality of the evidence supporting this result is moderate.
• Therapy with TOFA has no impact on the incidence of HZ during patient follow-up after LZV vaccination. The quality of the evidence supporting this result is moderate.

9. Is there evidence of a higher risk of venous thromboembolic events (VTEs) related to JAKi treatment?

In the search for evidence, 1541 studies (RCT) were retrieved and individually assessed by title and/or abstract, from which 30 references were selected for full text evaluation. Of the 30 studies, 10 were selected to support this evaluation [64–73] (Fig. 1). The reasons for exclusion and the list of excluded studies, as well as the description of the included studies, are available in the Additional file 9: Appendix 9.

Evidence summary

• There was no significant increase in the risk of VTE.
• The use of low doses of JAKi seemed to offer a lower risk of VTE than high doses. The quality of the evidence supporting this result is high.

Safety of JAKi in light of recent warnings

Although the present SLR has not shown unexpected findings regarding safety within each of the questions that guided the search, the authors considered necessary to discuss some recent data not covered in the SLR search period.

On Oral Surveillance study [74], the prespecified non-inferiority criteria for the co-primary endpoints of major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer), were not met for the primary comparison of the combined tofacitinib doses (5 mg twice daily and 10 mg twice daily) to TNF inhibitors (either etanercept 50 mg once weekly or adalimumab 40 mg every other week).

However, despite this trial wrapping in July 2020, its full results have been submitted but not yet published. Updates on this subject can be accessed at clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/results/NCT02092467).

In February 2021, a new “Food and Drug Administration” (FDA) warning regarding tofacitinib was issued [75]. FDA warned providers of an increased cardiovascular and cancer risk among older patients (> 50 years), compared with TNF-inhibitors. These warning has been based on interim and preliminary results from the ORAL Surveillance study [74].

In September 2021, FDA updated this previous warning, concluding that there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots and death related with Tofacitinib. Based on that conclusion, required “Boxed warning” addings and revisions for all JAKi, including these findings and limiting all approved uses to certain patients who have not responded or cannot tolerate one or more TNF blockers [75].

European Medicines Agency (EMA) has also recommended an update to the product information for tofacitinib, and uttered a reminding to healthcare professionals to carefully evaluate a patient’s individual benefit-risk profile when deciding to prescribe or continue the treatment [76].

Considering clinical aspects of the patients included in the post-marketing trial, who presented not only advanced age, but also other risk factors for unfavorable outcomes, we suggest taking into account the risk–benefit ratio when considering prescription of JAKi. For
patients already receiving JAKi, strict surveillance of those who meet the high-risk profile is recommended.

Also taking into account the recent data, the SBR RA committee decided to re-vote recommendations 5 and 9 (see Table 1), and a warning note was included for JAKi prescription, as it follows:

**Recommendation 5:** After failure of 2 csDMARD regimens, a bDMARD or a tsDMARD can be used, preferably combined with a csDMARD. Note: Carefully consider the use of tsDMARD in populations at risk for major cardiovascular events, thromboembolic and neoplastic events, including patients over 50 (and especially those over 65) with traditional risk factors for cardiovascular disease (particularly current or past smokers).

**Recommendation 9:** In case of failure of a bDMARD as initial treatment, a second bDMARD or a tsDMARD can be used. Note: Carefully consider the use of tsDMARD in risk groups for major cardiovascular events, thromboembolic and neoplastic events, including patients over 50 (and especially those over 65) with traditional risk factors for cardiovascular disease (particularly current or past smokers).

**Update of general assumptions and recommendations of the SBR committee on rheumatoid arthritis**

Based on the data previously presented and the voting process described, the RA Commission updated the therapeutic recommendations for RA in relation to the previous document [1]. Table 1 summarizes the general assumptions and recommendations of the SBR Rheumatoid Arthritis Committee for pharmacological treatment of RA in Brazil. The ones included in the present recommendations (5, 8, 9, 10 and 12) are highlighted in Table 1.
Flowchart for drug treatment of rheumatoid arthritis

Figure 1 summarizes the updated flowchart for drug treatment of RA in Brazil proposed by the RA Commission of the SBR.

Conclusions

Important advances in the management of RA patients are leading a better patient prognosis. Rheumatologists, as specialist, are most familiar with the range of drugs available and their indications and adverse effects and are
essential in the evaluation and treatment of patients diagnosed with RA.

The appropriate allocation of healthcare resources, especially in a country of continental dimensions and with a growing population, such as Brazil, conducts to access to drugs and appropriate technologies for the treatment of various conditions. These recommendations took into account, in addition to issues of safety, efficacy and cost, the experience of specialists in the management of RA, considering specific characteristics of Brazil, such as the availability of drugs and the socioeconomic level of the population.

Because the pace of knowledge acquisition in this field of science and the rise of new medications that are being analyzed for approval by Brazilian regulatory agencies, we recommend updating these guidelines every 2 years.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s42358-021-00228-x.

Additional file 1. PICO 1 - Are tsDMARD (JAK inhibitors) effective and safe for the treatment of RA patients in 1st line of treatment? (NOTE: "naïve" or treatment-naïve patients).
Additional file 2. PICO 2 - Are tsDMARD (JAK inhibitors) effective and safe for the treatment of RA patients after csDMARD failure?
Additional file 3. PICO 3 - Are tsDMARD (JAK inhibitors) effective and safe for the treatment of RA patients after bDMARD failure?
Additional file 4. PICO 4 - Are tsDMARD (JAK inhibitors) more effective for the treatment of RA patients compared to csDMARD?.
Additional file 5. PICO 5 - Are tsDMARD (JAK inhibitors) more effective for the treatment of RA compared to bDMARD?.
Additional file 6. PICO 6 - Is there any evidence of better cost-effectiveness of tsDMARD (JAK inhibitors) compared to csDMARD?.
Additional file 7. PICO 7 - Is there any evidence of better cost-effectiveness of tsDMARD (JAK inhibitors) compared to bDMARD?.
Additional file 8. PICO 8 - Is there any evidence for herpes zoster vaccination efficacy before starting tsDMARD (JAK inhibitor) treatment?.
Additional file 9. PICO 9 - Is there any evidence of an increased risk of thromboembolic events related to treatment with WMCDMae (JAK inhibitors)?

Acknowledgements
The authors wish to acknowledge the researcher Wanderley Bernardo, who is responsible for the systematic review—presented in detail in the supplementary material, funded by the Brazilian Society of Rheumatology.

Authors’ contributions
All authors made substantial contributions to the acquisition of data, have been involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of the version to be published and have participated sufficiently in the work to take public responsibility for appropriate portions of the content, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding
Brazilian Society of Rheumatology. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article, as “supplementary materials”.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors have read and approved the final version of this manuscript.

Competing interests
Karina Rossi Bonfiglioli: Personal fees and/or non-financial support from Pfizer, Abbvie, Roche, Novartis, Boehringer-Ingelheim. Financial competing interest: none. Non-financial competing interest: none. Licia Maria Henrique da Mota: Has received personal or institutional support from Abbvie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Boehringer-Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. Financial competing interest: none. Non-financial competing interest: none. Ana Cristina de Medeiros Ribeiro: No conflicts declared. Adriana Maria Kakehashi: Research funds: CNPq, SBR, FAPEMIG Support for Scientific Events: Abbvie, BMS, Janssen Lecture Fees: UC, Janssen, Pfizer, Roche, BMS Clinical research: Roche, Pfizer Advisory board: Janssen, Roche, BMS, Pfizer. Angela Luzia Branco Pinto Duarte: Lecture Fees: Janssen, BMS, Rina Dalva Neubarth Giorgi: Has received consulting fees, speaking fees and support for international congresses from Roche, Pfizer-Bristol-Myers-Squibb, UCB Pharma, Eli-Lilly, Abbvie, Novartis, Amgen, Biogen and Janssen. Ieda Maria Magalhaes Laurindo: Consultants for Abbvie, Amgen, Boehringer-Ingelheim, Bristol, GSK, Janssen, Lilly, Pfizer and UCB; has received personal or institutional support from Abbvie, Bristol, Janssen, Lilly, Pfizer, UCB; has delivered speeches at events related to this work and sponsored by Abbvie, Bristol, Janssen, Lilly, Pfizer, Roche and UCB. Financial competing interest: none. Non-financial competing interest: none. Mariana Peixoto Guimaraes Ubarajara e Silva de Souza: Support for Research, Scientific Events, Lecture: UCB, Abbvie, BMS, Novartis, Pfizer, Amgen, Sandoz, Roche. Ana Paula Monteiro Gomides: Assistance for participation in events: Pfizer. Claiton Viegas Brenol: Has participated in clinical and/or experimental studies related to this work and sponsored by the PI (Abbvie, BMS, Janssen, Pfizer and Roche); has received personal or institutional support from the PI (Abbvie, BMS, Janssen, Pfizer and Roche); has delivered speeches at events related to this work and sponsored by the PI (Abbvie, Janssen, Pfizer and Roche). Financial competing interest: none. Non-financial competing interest: none. Geraldo da Rocha Castellar Pinheiro: No conflicts declared. Charles Heldan de Moura Castro: No conflicts declared. Cândido Pires de Albuquerque: Personal fees and/or non-financial support from Abbvie, Pfizer, AstaZeneca, Janssen, Bristol-Myers-Squibb, Roche, Novartis and UCB, outside the submitted article. Gustavo Luiz Behrens Pinto: Personal fees and/or non-financial support from Abbvie, Roche and Novartis, outside the submitted article. Jose Fernando Verztman: Personal fees and/or non-financial support from Pfizer, Abbvie, AstaZeneca, Janssen, Bristol-Myers-Squibb, Roche, Novartis and UCB, outside the submitted article. Jose burger: Personal fees and/or non-financial support from Abbvie, Pfizer, UCB, Roche, Novartis, Janssen, Lilly, Financial competing interest: none. Non-financial competing interest: none. Luciana Feitosa Muniz: No conflicts declared. Manoel Barros Bertolo: Has participated in clinical and/or experimental studies related to this work and sponsored by the PI (Abbvie, BMS, Janssen, Pfizer and Roche); has received personal or institutional support from the PI (Abbvie, BMS, Janssen, Pfizer and Roche); has delivered speeches at events related to this work and sponsored by the PI (Abbvie, Pfizer). Financial competing interest: none. Non-financial competing interest: none. Maria Raquel da Costa Pinto: Support in Congresses: UCB, Roche, Janssen, Bristol, Pfizer, Boehringer. Advisory Board: Janssen. Paulo Louzada Júnior: Sponsored by: Bristol-Myers Squibb, UCB, Pfizer Board Participation: Pfizer Vitor Alves Cruz: Support in Congresses: UCB, Janssen, Abbvie and Pfizer. Ivanio Alves Pereira: Has received personal fee for lectures from Abbvie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Janssen, Pfizer and Roche.

All authors have read and approved the final manuscript.
to this work and sponsored by Abbvie, Boheringer-Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. Financial competing interest: none. Non-financial competing interest: none. Max Vitor Caroia de Fretas: Speaker at events related to this work and sponsored by Abbvie, Novartis, Roche, Pfizer and UCB. Managing Partner of Integrare Therapeutics. Bôris Alfonso Cruz: Support for Scientific Events and Lecture Fees: Abbvie, BMS, Janssen, Novartis, Pfizer, Roche. Eduardo Paiva: No conflicts declared. Odrelle Monticelli: Lectures and consultancies: Abbvie, ASPEN, BMS, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, UCB. José Roberto Provenza: No conflicts declared. Ricardo Machado Xavier: Lectures, consultancies: Abbvie, BMS, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, UCB Clinical trials: Abbvie, UCB, Pfizer, GSK, Lilly.

Author details
1 Disciplina Reumatologia do Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), Av. Dr. Arnaldo, 455 - 3° andar – Reumatologia, São Paulo, SP, CEP 01246-903, Brazil. 2 Serviço de Reumatologia do Hospital, Universitário de Brasília (HU/UnB), Brasília, Brazil. 3 Serviço de Reumatologia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil. 4 Disciplina de Reumatologia, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil. 5 Serviço de Reumatologia, Hospital do Servidor Público Estadual de São Paulo (HSPE-IAMSPE), São Paulo, Brazil. 6 Universidade Federal de Pernambuco (UFPE), Recife, Brazil. 7 Santa Casa de Belo Horizonte (MG), Belo Horizonte, Brazil. 8 Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (HCW/UFRRGS), Porto Alegre, Brazil. 9 Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Brazil. 10 Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. 11 Universidade Federal da Bahia (UFBA), Salvador, Brazil. 12 Hospital Federal dos Servidores do Estado do RJ, Rio de Janeiro, Brazil. 13 Hospital Regional de Sobradinho (DF), Brasilia, Brazil. 14 Disciplina de Reumatologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil. 15 Disciplina de Reumatologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP-RP), Ribeirão Preto, Brazil. 16 Disciplina de Reumatologia, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, Brazil. 17 Serviço de Reumatologia do Hospital Universitário, Universidade Federal de Santa Catarina (USP-RP), Curitiba, Brazil. 18 Disciplina de Reumatologia da Pontificia, Universidade Católica de Campinas, PUC-Campinas, Campinas, Brazil.

Received: 25 June 2021 Accepted: 5 November 2021

Published online: 24 November 2021

References
1. Mota LMHD, Kakehasi AM, Gomides APM, et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018;58(1):2. https://doi.org/10.1186/s42358-018-0005-0.
2. Alamanos Y, Voulgaris PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–8.
3. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54:944–7.
4. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007;21:929–42.
5. Klaerenbeek NB, Allaart CF, Kersten Pj, Huizinga Tw, Dijkmans Ba. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21:291–8.
6. Ghahri S, Binard A, Pers Ym, Maounfury F, Caro Jj. Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in France. Value Health. 2020;23(4):461–70. https://doi.org/10.1016/j.jval.2019.12.003.
7. Smolen Js, Landewe Rb, Bijlsma Jw, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–90. https://doi.org/10.1136/annrheumdis-2019-216655.
8. Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10(7):E1002. https://doi.org/10.3390/biom10071002.
9. Bula Tofacitinib, Aug. 10, 2020.
10. Bula Upadacitinib.
11. Moher D, Shamseer L, Clarke M, Gnersi D, Liberati A, Petticrew M, Shekelle P, Stewart L. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1.
12. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
13. GRADECpr GDT-GRADEdpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.): gradepro.org.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
15. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584.
16. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(3):2377–86.
17. Fleischmann R, Schiff M, van der Heijde D, Ramos-Reums C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(Suppl 10):S586–7.
18. van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT- EARLY): a randomised, double-blind, active-comparator, multi-center, multi-country trial [published online ahead of print, 2020 Jul 8]. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41384.
19. Li Z, Hu J, Bao C, Li X, Xu J, Spindler A, et al. SAT0218 Efficacy and safety of baricitinib in mts-r patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). Ann Rheum Dis. 2018;77(Suppl 2):969.
20. Tanaka Y, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. SAT0257 a phase 2b/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective Jak1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic dmard: results from the RA- BUILD study. Ann Rheum Dis. 2018;77(Suppl 2):991.
21. Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12.
22. Dougados M, van der Heijde D, Chen YC, Greenwald M, Descher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA- BUILD study. Ann Rheum Dis. 2017;76(1):88–95.
23. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis: N Engl J Med. 2017;376(9):1652–62.
24. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomised, placebo-controlled study. J Rheumatol. 2016;43(3):504–11.
25. Keystone EC, Taylor PC, Descher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–40.
26. Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazar M, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998–1008.
28. Kavanaugh A, Kremer J, Ponce L, Czeuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634/JS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomized, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009–19.

29. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomized, double-blind, placebo-controlled trial (RA44) in Japan. Ann Rheum Dis. 2019;78(10):1305–19.

30. Krivit AJ, Gutierrez-Aurea SR, Polley J, Genovese MC, Kristy R, Shay K, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–19.

31. Fleischmann R, Myers E, Hall S, Krivit AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, andadalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial. Lancet. 2017;390(10093):457–68.

32. van der Heijde D, Tanaka Y, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19.

33. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein SD, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(37):1243–52.

34. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis, and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–66.

35. Fleischmann R, Pangan AL, Song IH, Myers E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800.

36. Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheumatol. 2012;64(4):970–81.

37. Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150–8.

38. van der Heijde D, Tanaka Y, Fleischmann R, Keaystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.

39. Genovese MC, Smolen JS, Holloway D, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19.

40. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein SD, et al. Baricitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019;22(8):777–87.

41. Claxton L, Jenks M, Taylor M, Wallenstein G, Mendelsohn AM, Bourret JA, Leonardis F, De La Torre I, Van De Laar MA. Cost-effectiveness of a JAK1/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. ClinicoEconomics Outcomes Res: CEOR. 2019;11:395.

42. Claxton L, Jenks M, Taylor M, Wallenstein G, Mendelsohn AM, Bourret JA, Leonardis F, De La Torre I, Van De Laar MA. Cost-effectiveness of a JAK1/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. ClinicoEconomics Outcomes Res: CEOR. 2019;11:395.
methotrexate: a post hoc analysis of data from a phase IIIb/IV randomized study. Arthritis Care Res (Hoboken). 2020;72:353–9.
61. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969–77.
62. Winthrop KL, Wouters A, Choy EH, Chen C, Biswas P, Wang L, et al. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Ann Rheum Dis. 2020;79:669–71.
63. Stevens E, Weinblatt ME, Massarotti E, Griffin F, Emani S, Desai S. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. ACR Open Rheumatol. 2020. https://doi.org/10.1002/acr2.11150.
64. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071.
65. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [published correction appears in N Engl J Med. 2013 Jul 18;369(3):293]. N Engl J Med. 2012;367(6):508–19. https://doi.org/10.1056/NEJMoa111207.
66. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–60. https://doi.org/10.1016/S0140-6736(12)61424-X.
67. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs: SELECT-BEYOND, a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–24. https://doi.org/10.1016/S0140-6736(18)31116-4.
68. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT), a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12. https://doi.org/10.1016/S0140-6736(18)31115-2.
69. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomised controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800. https://doi.org/10.1002/art.41032.
70. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, placebo-controlled study. J Rheumatol. 2016;43(5):998. https://doi.org/10.3899/jrheum.150613.C1.
71. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. https://doi.org/10.1136/annrheumdis-2016-210094.
72. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–62. https://doi.org/10.1056/NEJMoa1608345.
73. Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial [published correction appears in JAMA. 2020 Feb 4;323(5):480]. JAMA. 2019;322(4):315–25. https://doi.org/10.1001/jama.2019.9055.
74. https://clinicaltrials.gov/ct2/show/results/NCT02092467. Last checked in 30 Sept 2021.
75. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requi res-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Last checked in 30 Sept 2021.
76. https://www.ema.europa.eu/en/news/meeting-highl ights-pharmaco vi gilance-risk-assessment-committee-ptac-7-10-june-2021. Last checked in 30 Sept 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.